Malign ve prekanseröz larengeal lezyonlarda nötrofil lenfosit oranı ve trombosit lenfosit oranı

Amaç: Bu çalışmada, prekanseröz larengeal lezyonu veya larengeal skuamöz hücreli karsinoması olan hastalarda nötrofil lenfosit oranı NLO ve trombosit lenfosit oranı TLO arasındaki ilişki araştırıldı.Hastalar ve Yöntemler: Bu retrospektif çalışmaya Ocak 2011 - Haziran 2016 tarihleri arasında histopatoloji sonucuna göre prekanseröz larengeal lezyon veya larengeal skuamöz hücreli karsinoma tanısı konulan 98 hasta 92 erkek, 6 kadın; ort. yaş 57.4±11.3 yıl; dağılım 32-82 yıl dahil edildi. Hastalar prekanseröz larengeal lezyonlu veya larengeal skuamöz hücreli karsinomalı olmak üzere iki gruba ayrıldı.Bulgular: İki grup arasında NLO ve TLO değerleri açısından istatistiksel olarak anlamlı farklılık vardı sırasıyla, p=0.010, p=0.002 . Larengeal skuamöz hücreli karsinomalı hastalar lenf nodu metastazı, tümörün primer yerleşimi ve tümörün diferansiasyonu açısından değerlendirildiğinde, NLO ve TLO değerleri arasında istatistiksel olarak anlamlı farklılık yoktu. Ancak klinik evrelendirme açısından değerlendirildiğinde, TLO değeri istatistiksel olarak farklı p=0.047 , NLO değeri ise istatistiksel olarak farklı değildi.Sonuç: Bildiğimiz kadarıyla, bu çalışma, TLO’nun prekanseröz larengeal lezyon ve larengeal skuamöz hücreli karsinomanın ayrımında kullanabileceğini gösteren ilk çalışmadır

Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in malignant and precancerous laryngeal lesions

Objectives: This study aims to investigate the relationship between neutrophil to lymphocyte ratio NLR and platelet to lymphocyte ratio PLR in patients with precancerous laryngeal lesion or laryngeal squamous cell carcinoma. Patients and Methods: This retrospective study included 98 patients 92 males, 6 females; mean age 57.4±11.3 years; range 32 to 82 years who were diagnosed to have precancerous laryngeal lesion or laryngeal squamous cell carcinoma according to histopathology result between January 2011 and June 2016. Patients were divided into two groups as those with precancerous laryngeal lesion or laryngeal squamous cell carcinoma. Results: There was a statistically significant difference between the two groups in terms of NLR and PLR values p=0.010, p=0.002, respectively . When patients with laryngeal squamous cell carcinoma were evaluated in terms of lymph node metastasis, primary localization of tumor and differentiation of tumor; there was no statistically significant difference between NLR and PLR values. However, when evaluated in terms of clinical staging, PLR value was statistically different p=0.047 while NLR value was not statistically different. Conclusion: To our knowledge, this is the first study to show that PLR can be used to differentiate precancerous laryngeal lesion and laryngeal squamous cell carcinoma.

___

  • Ferlito A, Devaney KO, Woolgar JA, Slootweg PJ, Paleri V, Takes RP, et al. Squamous epithelial changes of the larynx: diagnosis and therapy. Head Neck 2012;34:1810-6.
  • Fu Y, Liu W, OuYang D, Yang A, Zhang Q. Preoperative Neutrophil-to-lymphocyte Ratio Predicts Long-term Survival in Patients Undergoing Total Laryngectomy With Advanced Laryngeal Squamous Cell Carcinoma: A Single-center Retrospective Study. Medicine (Baltimore) 2016;95:2689.
  • Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, et al. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer 2015;112:1088-97.
  • Koh CH, Bhoo-Pathy N, Ng KL, Jabir RS, Tan GH, See MH, et al. Utility of pre-treatment neutrophil- lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer 2015;113:150-8.
  • Ozawa T, Ishihara S, Nishikawa T, Tanaka T, Tanaka J, Kiyomatsu T, et al. The preoperative platelet to lymphocyte ratio is a prognostic marker in patients with stage II colorectal cancer. Int J Colorectal Dis 2015;30:1165-71.
  • Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
  • Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 2013;24:130-7.
  • Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M. The platelet-cancer loop. Eur J Intern Med 2013;24:393-400.
  • Sullivan LA, Brekken RA. The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2010;2:165-75.
  • Mantovani A, Allavena P, Sica A, Balkwill F. Cancer- related inflammation. Nature 2008;454:436-44.
  • Lança T, Silva-Santos B. The split nature of tumor- infiltrating leukocytes: Implications for cancer surveillance and immunotherapy. Oncoimmunology 2012;1:717-725.
  • Wong BY, Stafford ND, Green VL, Greenman J. Prognostic value of the neutrophil-to-lymphocyte ratio in patients with laryngeal squamous cell carcinoma. Head Neck 2016;38:1903-8.
  • Kum RO, Ozcan M, Baklaci D, Kum NY, Yilmaz YF, Gungor V, et al. Elevated neutrophil-to-lymphocyte ratio in squamous cell carcinoma of larynx compared to benign and precancerous laryngeal lesions. Asian Pac J Cancer Prev 2014;15:7351-5.
  • Tu XP, Qiu QH, Chen LS, Luo XN, Lu ZM, Zhang SY, et al. Preoperative neutrophil-to-lymphocyte ratio is an independent prognostic marker in patients with laryngeal squamous cell carcinoma. BMC Cancer 2015;15:743.
  • Gong W, Yang S, Yang X, Guo F. Blood preoperative neutrophil-to-lymphocyte ratio is correlated with TNM stage in patients with papillary thyroid cancer. Clinics (Sao Paulo) 2016;71:311-4.
  • Li H, Song J, Cao M, Wang G, Li L, Zhang B, et al. Preoperative neutrophil-to-lymphocyte ratio is a more valuable prognostic factor than platelet-to- lymphocyte ratio for nonmetastatic rectal cancer. Int Immunopharmacol 2016;40:327-31.
  • Liu C, Huang Z, Wang Q, Sun B, Ding L, Meng X, et al. Usefulness of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in hormone- receptor-negative breast cancer. Onco Targets Ther 2016;9:4653-60.
  • Han Y, Wang J, Hong L, Sun L, Zhuang H, Sun B, et al. Platelet-lymphocyte ratio is an independent prognostic factor in patients with ALK-positive non- small-cell lung cancer. Future Oncol 2017;13:51-61.